FATE THERAPEUTICS, I

FATE

Real-time Estimate - 06/18 10:11:04 am
81.605USD	-3.09%

08/09/21	Interim 2021 Earnings Release (Projected)
11/10/21	Q3 2021 Earnings Release (Projected)
03/07/22	FY 2021 Earnings Release (Projected)
05/11/22	Q1 2022 Earnings Release (Projected)

06/15/21 \| 05:30pm	Bank of America Securities Napa Biopharma Virtual Conference
06/04/21	American Society of Clinical Oncology Conference
06/02/21	Annual General Meeting
06/01/21 \| 01:00pm	Jefferies Healthcare Conference

06/22/21	BIONTECH SE : Annual General Meeting
06/22/21 \| 08:00am	REGENERON PHARMACEUTICALS : BMO Biopharma Day
07/28/21	GILEAD SCIENCES, INC. : Interim 2021 Earnings Release (Projected)
07/28/21	VERTEX PHARMACEUTICALS : Interim 2021 Earnings Release (Projected)

06/11/21 \| 10:30am	REGENERON PHARMACEUTICALS : Annual General Meeting
06/11/21 \| 03:00am	VERTEX PHARMACEUTICALS : European Hematology Association Congress - Abstract #EP736
06/11/21 \| 03:00am	VERTEX PHARMACEUTICALS : European Hematology Association Congress - Abstract #EP733
06/10/21 \| 04:30pm	VERTEX PHARMACEUTICALS INCORPORATED : VX-864 Phase 2 Study Results Call

Previous year

Next Year

Annual results		2016	2017	2018	2019	2020	2021 (e)
Sales M $	Released Forecast Spread	4,40 4,35 1,1%	4,11 4,02 2,2%	4,74 4,08 16%	10,7 9,62 11%	31,4 20,6 53%	32,9
Operating income (EBITDA) M $	Released Forecast Spread	-32,0 -33,1 3,5%	-42,1 -40,8 -3,3%	-67,1 -65,9 -1,7%	-101 -99,9 -0,82%	-128 -130 1,3%	-201
Operating profit (EBIT) M $	Released Forecast Spread	-33,5 -34,9 4,1%	-43,0 -41,5 -3,4%	-66,6 -65,6 -1,5%	-98,1 -97,4 -0,72%	-173 -146 -19%	-203
Pre-Tax Profit (EBT) M $	Released Forecast Spread	-33,5 -35,0 4,3%	-43,0 -41,6 -3,3%	-66,6 -66,0 -0,98%	-98,1 -97,8 -0,40%	-173 -147 -18%	-200
Net income $	Released Forecast Spread	-1,05 -1,14 7,5%	-1,02 -0,97 -5,2%	-1,19 -1,18 -0,73%	-1,44 -1,44 0,21%	-2,10 -1,82 -16%	-2,13
Announcement Date		03/16/2017	03/05/2018	03/05/2019	03/02/2020	02/24/2021

Previous period

Next period

Quarterly results		2018 Q4	2019 Q1	2019 Q2	2019 Q3	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2 (e)	2021 Q3 (e)	2021 Q4 (e)	2022 Q1 (e)	2022 Q2 (e)
Sales M $	Released Forecast Spread	1,66 1,02 63%	2,63 2,01 31%	2,82 1,09 159%	2,43 1,75 38%	2,80 1,70 65%	2,52 1,69 49%	5,47 10,9 -50%	7,56 7,49 0,90%	15,9 5,05 215%	11,1 6,70 66%	6,90	6,95	8,42	8,49	9,93
Operating income (EBITDA) M $	Released Forecast Spread	-16,7 -18,0 7,2%	-20,4 -16,3 -25%	-24,1 -22,5 -7,0%	-27,1 -25,6 -6,1%	-29,1 -28,3 -2,6%	-34,5 -30,1 -15%	-28,7 -22,3 -29%	-31,5 -28,3 -11%	-33,4 -35,1 4,8%	-46,2 -40,9 -13%	-50,8	-53,0	-53,8	-58,6	-59,7
Operating profit (EBIT) M $	Released Forecast Spread	-16,0 -18,2 12%	-19,8 -15,8 -25%	-23,5 -21,7 -8,3%	-26,6 -25,3 -5,0%	-28,3 -27,9 -1,3%	-33,5 -29,7 -13%	-28,1 -21,1 -33%	-58,7 -27,2 -116%	-53,1 -33,3 -59%	-45,1 -40,3 -12%	-50,6	-52,7	-54,4	-56,9	-58,2
Pre-Tax Profit (EBT) M $	Released Forecast Spread	-16,0 -18,0 11%	-19,8 -16,2 -22%	-23,5 -21,7 -8,1%	-26,6 -25,5 -4,5%	-28,3 -28,2 -0,23%	-33,5 -29,3 -15%	-28,1 -21,6 -30%	-58,7 -27,2 -116%	-53,1 -33,7 -58%	-45,1 -39,5 -14%	-49,8	-51,9	-52,9	-56,9	-58,2
Net income $	Released Forecast Spread	-0,25 -0,25 0,79%	-0,30 -0,23 -29%	-0,36 -0,33 -10%	-0,40 -0,38 -5,3%	-0,37 -0,39 4,9%	-0,44 -0,39 -13%	-0,35 -0,29 -22%	-0,68 -0,32 -110%	-0,61 -0,39 -57%	-0,44 -0,43 -1,6%	-0,53	-0,55	-0,56	-0,62	-0,64
Announcement Date		03/05/2019	05/07/2019	08/06/2019	11/05/2019	03/02/2020	05/11/2020	08/05/2020	11/05/2020	02/24/2021	05/05/2021